Ligand Pharma CFO Sells $688K in Stock as Shares Surge 80% This Past Year. Here's What to Know
The Big Market Report Take
This royalty-focused biotech with a broad drug portfolio reported a notable insider sale amid strong stock performance.
Related Guides
Not financial advice. The Big Market Report aggregates news for informational purposes only. Nothing on this site constitutes investment advice. Equities and other securities are subject to market risk. Always do your own research and consult a qualified financial advisor before making any investment decisions. Full disclaimer →
Never miss a story
More from this section
Carnival Gets Hit By the Iran War. Can the Cruise Stock Bounce Back?The Motley Fool41m ago- Consumer Sentiment Plunges 6% Amid Energy Price Spikes And Market VolatilitySeeking Alpha41m ago
Is Tecnoglass Stock a Buy After Energy Holdings Scooped Up Shares Worth $13.1 Million?The Motley Fool54m ago
Ethereum and Solana Just Got a Huge Catalyst. Should You Buy Them With $1,000?The Motley Fool56m ago
Stoke Therapeutics Stock Up 340% as Chair Sells $174K in SharesThe Motley Fool1h ago